Sign in

    Unknown Analyst • Stifel, Nicolaus & Company, Incorporated

    Unknown Analyst's questions to LeMaitre Vascular Inc (LMAT) leadership

    Unknown Analyst's questions to LeMaitre Vascular Inc (LMAT) leadership • Q2 2025

    Question

    An analyst from Stifel, on behalf of Rick Wise, asked for an update on the company's sales force expansion plans towards its year-end target and inquired about the outlook for international sales growth in the second half of the year.

    Answer

    Chairman & CEO George LeMaitre revised the year-end sales rep target to around 165, down slightly from 170, noting the current distribution is 77 in the Americas, 57 in Europe, and 30 in APAC. He highlighted strong European growth driven by the ArteGraft launch and an expected RestoreFlow launch, but also pointed to a strong turnaround in the Americas, which grew 15% organically in Q2.

    Ask Fintool Equity Research AI

    Unknown Analyst's questions to Compass Pathways PLC (CMPS) leadership

    Unknown Analyst's questions to Compass Pathways PLC (CMPS) leadership • Q4 2024

    Question

    An analyst from Stifel, on behalf of Paul Mattis, inquired about the specific details to be disclosed in the upcoming COMP005 top-line data readout and asked for an update on the trial's enrollment status.

    Answer

    CEO Kabir Nath clarified that the 6-week top-line disclosure will include the MADRS effect size difference between arms, the associated p-value, and confidence intervals. For safety, a high-level statement from the DSMB will be provided. He also reported that the COMP005 trial is over 90% recruited, with COMP006 also enrolling well.

    Ask Fintool Equity Research AI